Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-15.30 Insider Own0.20% Shs Outstand8.36M Perf Week0.00%
Market Cap66.04M Forward P/E- EPS next Y-5.06 Insider Trans- Shs Float8.02M Perf Month-30.40%
Income-47.10M PEG- EPS next Q-1.29 Inst Own81.30% Short Float2.47% Perf Quarter-31.90%
Sales- P/S- EPS this Y87.40% Inst Trans0.01% Short Ratio5.78 Perf Half Y-35.62%
Book/sh4.86 P/B1.63 EPS next Y11.50% ROA-83.00% Target Price32.67 Perf Year-62.50%
Cash/sh7.18 P/C1.10 EPS next 5Y- ROE-98.90% 52W Range7.45 - 23.10 Perf YTD-32.19%
Dividend- P/FCF- EPS past 5Y-25.60% ROI- 52W High-65.80% Beta-
Dividend %- Quick Ratio11.40 Sales past 5Y- Gross Margin- 52W Low6.10% ATR0.52
Employees20 Current Ratio11.40 Sales Q/Q- Oper. Margin- RSI (14)28.42 Volatility4.93% 6.19%
OptionableNo Debt/Eq0.36 EPS Q/Q94.10% Profit Margin- Rel Volume1.71 Prev Close7.65
ShortableYes LT Debt/Eq0.36 EarningsMar 28 AMC Payout- Avg Volume34.28K Price7.90
Recom1.30 SMA20-12.12% SMA50-23.61% SMA200-39.01% Volume58,528 Change3.27%
Apr-24-17 08:00AM  Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago PR Newswire
Apr-21-17 08:00AM  Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 PR Newswire
Apr-18-17 08:00AM  Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia PR Newswire
Apr-06-17 08:00AM  Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting PR Newswire -15.74%
Mar-28-17 01:04PM  EIGER BIOPHARMACEUTICALS, INC. Financials
09:50AM  New Strong Buy Stocks for March 28th
Mar-23-17 08:10AM  Eiger BioPharma reports 4Q loss Associated Press
08:04AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
06:06AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 08:00AM  Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017 PR Newswire
Jan-30-17 08:00AM  Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PR Newswire
Jan-05-17 04:08PM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F
Jan-04-17 08:00AM  Eiger Completes $25 Million Debt Financing with Oxford Finance PR Newswire
Jan-03-17 08:00AM  Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) PR Newswire
Dec-14-16 06:21PM  How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers Insider Monkey
Dec-12-16 08:00AM  Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Dec-01-16 08:44AM  Eiger BioPharmaceuticals, Inc. :EIGR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
Nov-29-16 08:00AM  Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) PR Newswire
Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.